NASDAQ:CLLSCellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLLS stock has increased by 63.2% and is now trading at $18.65. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) posted its earnings results on Wednesday, May, 6th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $1.06. The biotechnology company had revenue of $51.91 million for the quarter, compared to analyst estimates of $21.07 million. Cellectis had a negative net margin of 93.27% and a negative return on equity of 17.60%. View Cellectis' earnings history.

7 Wall Street analysts have issued 1-year target prices for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' share price to reach $32.33 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price. View analysts' price targets for Cellectis.

News coverage about CLLS stock has been trending negative on Monday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectis earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Cellectis.

Cellectis saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 256,900 shares, a drop of 16.9% from the June 15th total of 309,200 shares. Based on an average trading volume of 208,700 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.6% of the shares of the stock are sold short. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), I-Mab (BDTX), Sorrento Therapeutics (SRNE), Regenxbio (RGNX), Mesoblast (MESO), Sangamo Therapeutics (SGMO) and Cortexyme (CRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Intellia Therapeutics (NTLA), Sarepta Therapeutics (SRPT) and Alibaba Group (BABA).

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $18.65.

Cellectis has a market capitalization of $792.07 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]